
CorMedix (CRMD) Stock Forecast & Price Target
CorMedix (CRMD) Analyst Ratings
Bulls say
Cormedix Inc. is positioned for substantial growth driven by its product DefenCath, particularly with its expansion into total parenteral nutrition (TPN), which could significantly enhance revenue potential beyond initial forecasts. The company expects a three to fivefold improvement in pricing due to the TDAPA formula, as well as robust sales projections ranging from $100 million to $140 million by 2027, reflecting the growing utilization among outpatient dialysis customers. Additionally, ongoing enhancements in treatment tolerability and the anticipated increase in patient uptake suggest further upside opportunities that are not fully accounted for in current revenue models.
Bears say
Cormedix Inc faces a negative outlook primarily due to its downward revenue guidance for 2026, with projections of $300MM-$320MM falling significantly short of market consensus expectations of $423MM. The anticipated transition to a post-TDAPA Add-On Adjustment starting July 1, 2026, is expected to result in significantly reduced reimbursement and net pricing for its product, DefenCath, particularly impacting the second half of the year. Additionally, competition from generics, such as Heparin, poses further risk to meeting sales projections for catheter lock solutions, suggesting potential challenges in achieving sustainable revenue growth.
This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.
CorMedix (CRMD) Analyst Forecast & Price Prediction
Start investing in CorMedix (CRMD)
Order type
Buy in
Order amount
Est. shares
0 shares